Connect to other sites within the UBM Medica Network
Financial Burden of Multiple Myeloma High, Even Among Insured
Seventy percent of insured patients with multiple myeloma had treatment-related financial burden, including some with household incomes greater than $100,000 a year.
Ixazomib Gets Priority Review for Multiple Myeloma
The FDA recently granted priority review status to ixazomib (Takeda) for the treatment of relapsed or refractory multiple myeloma.
Agent Orange Exposure Linked to Myeloma Precursor Risk
Vietnam War veterans exposed to Agent Orange as part of Operation Ranch Hand were at double the risk for monoclonal gammopathy of undetermined significance, a precursor to multiple myeloma, according to results of a new study.
Monoclonal Antibody Effective in Refractory Myeloma
Daratumumab, a monoclonal antibody that targets CD38, was safe and effective in patients with heavily pretreated and refractory multiple myeloma.
Continuous Therapy Delayed Progression in Newly Diagnosed Myeloma
Continuous therapy resulted in delays in first and second progression compared with fixed-duration therapy in patients with newly diagnosed multiple myeloma.
Staging System Revised for Multiple Myeloma
The International Myeloma Working Group has published a revised International Staging System for multiple myeloma that incorporates chromosomal abnormalities.
Engineered T Cells Elicit Clinical Response in Advanced Myeloma
Eighty percent of patients with advanced multiple myeloma had a clinical response to a new T cell–receptor therapy that used T cells to target cells expressing NY-ESO-1.
By clicking Accept, you agree to become a member of the UBM Medica Community.